Abstract
Fluoroquinolones (FQ) play an essential role in the treatment and control of multidrug-resistant tuberculosis (MDR-TB). They are also being evaluated as part of newer regimens under development for drug-sensitive TB. As newer FQ-based regimens are explored, knowledge of FQ resistance data from high TB burden countries becomes essential. We examine available FQ resistance data from high TB burden countries and demonstrate the need for comprehensive surveys to evaluate FQ resistance in these countries. The factors driving FQ resistance in such conditions and the cost of such resistance to weak healthcare systems are discussed. The need for a comprehensive policy for addressing the issue of FQ resistance is highlighted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 118-123 |
| Number of pages | 6 |
| Journal | International Journal of Infectious Diseases |
| Volume | 32 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Drug-resistant tuberculosis
- Fluoroquinolone resistance
- Health systems
- Tuberculosis
Fingerprint
Dive into the research topics of 'Fluoroquinolone-resistant tuberculosis: Implications in settings with weak healthcare systems'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver